加载中
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
常规交易时段
US$1.215
−US$0.105 · -7.95%
盘中时间采用ET。市场数据可能有所延迟。
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
日内区间
当前US$1.215
52周区间
当前US$1.215
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
46
合理估值
情绪
59
多空交织
风险
68
高风险
动量
74
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
日内区间
当前US$1.215
52周区间
当前US$1.215
营业利润
净利润
| 项目（USD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 销货成本 | — | 22.94万 USD | — | — | — |
| 毛利 | — | −22.94万 USD | — | — | — |
| 研究与开发 | 1396.24万 USD | 926.67万 USD | 2310.04万 USD | 3329.95万 USD | 1725.83万 USD |
| 销售、一般及管理费用 | 851.1万 USD | 857.01万 USD | — | 1155.16万 USD | — |
| 营业费用 | 2265.17万 USD | 1783.68万 USD | 3217.96万 USD | 4508.04万 USD | 2725.3万 USD |
| 利息收入 | 59.68万 USD | 85.3万 USD | 113.67万 USD | 56.23万 USD | 4.41万 USD |
| 利息支出 | 1.79万 USD | 33.27万 USD | 289.39万 USD | 430.02万 USD | 216.3万 USD |
| 折旧和摊销 | 17.83万 USD | 22.94万 USD | 22.94万 USD | 22.94万 USD | 22.94万 USD |
| 营业利润 | −2265.17万 USD | −1806.62万 USD | −3217.96万 USD | −4508.04万 USD | −2725.3万 USD |
| 净利润 | −2207.29万 USD | −1754.21万 USD | −3212.05万 USD | −5025.58万 USD | −2608.45万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
